首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   25321篇
  免费   1912篇
  国内免费   57篇
耳鼻咽喉   275篇
儿科学   947篇
妇产科学   833篇
基础医学   3388篇
口腔科学   283篇
临床医学   3282篇
内科学   4449篇
皮肤病学   550篇
神经病学   2394篇
特种医学   572篇
外科学   2693篇
综合类   302篇
一般理论   71篇
预防医学   3422篇
眼科学   343篇
药学   1683篇
中国医学   22篇
肿瘤学   1781篇
  2023年   272篇
  2022年   164篇
  2021年   666篇
  2020年   508篇
  2019年   855篇
  2018年   881篇
  2017年   672篇
  2016年   673篇
  2015年   743篇
  2014年   1001篇
  2013年   1464篇
  2012年   2168篇
  2011年   2291篇
  2010年   1177篇
  2009年   1075篇
  2008年   1691篇
  2007年   1803篇
  2006年   1625篇
  2005年   1422篇
  2004年   1254篇
  2003年   1112篇
  2002年   1026篇
  2001年   207篇
  2000年   165篇
  1999年   174篇
  1998年   173篇
  1997年   125篇
  1996年   88篇
  1995年   100篇
  1994年   85篇
  1993年   67篇
  1992年   124篇
  1991年   127篇
  1990年   110篇
  1989年   105篇
  1988年   100篇
  1987年   93篇
  1986年   87篇
  1985年   78篇
  1984年   70篇
  1983年   63篇
  1982年   48篇
  1981年   39篇
  1980年   31篇
  1979年   52篇
  1978年   46篇
  1976年   26篇
  1974年   39篇
  1973年   39篇
  1972年   28篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Quality of Life Research - Quality of life can be negatively impacted by the formation of a stoma and is influenced by a number of factors. Research to date treats people with a stoma as a...  相似文献   
2.
3.
Maternal and Child Health Journal - The purpose of this study was to explore the postpartum experiences of publicly-insured women of color, and identify how postpartum care can be improved to...  相似文献   
4.
5.
Purpose

Bullying is associated with a heightened risk for poor outcomes, including psychosis. This study aimed to replicate previous findings on bullying prevalence in clinical high-risk (CHR) individuals, to assess the longitudinal course of clinical and functional variables between bullied and non-bullied CHR and the association of bullying with premorbid functioning, clinical outcome, transition to psychosis and risk of violence.

Methods

The sample consisted of 691 CHR participants and 96 healthy controls. Participants reported whether they had experienced bullying and how long it had lasted. Assessments included DSM-5 diagnoses, attenuated psychotic symptoms, negative symptoms, social and role functioning, depression, stress, premorbid functioning, and risk of violence. The bullied and non-bullied CHR groups were compared at baseline and further longitudinally on clinical and functioning variables and transition to psychosis.

Results

Bullying was more prevalent among CHR individuals than healthy controls. Bullied CHR had a higher prevalence of PTSD and more severe depression and stress at baseline than non-bullied CHR. There was no impact of bullying on clinical and functional variables over time. Bullying was not related to final clinical status or transition to psychosis. However, bullied participants had poorer premorbid functioning and a greater risk of violence.

Conclusion

While bullying may not impact the likelihood of CHR individuals to transition to psychosis, it may be a risk factor for development of the at-risk state and may be related to a greater risk of violence. Future studies should consider bullying perpetration among CHR individuals.

  相似文献   
6.
Cancer Causes & Control - A disparity exists in cancer screening rates for the Sexual and Gender Minority (SGM) community. We sought to understand the perceptions and baseline knowledge of...  相似文献   
7.
8.
9.
10.
Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in breast and recurrent gynecologic cancer patients. Veliparib and PLD were administered in a standard phase 1, 3 + 3 dose-escalation design starting at 50 mg veliparib BID on days 1–14 with PLD 40 mg/mg2 on day 1 of a 28-day cycle. Dose escalation proceeded in two strata: A (prior PLD exposure) and B (no prior PLD exposure). Patients underwent limited pharmacokinetic (PK) sampling; an expansion PK cohort was added. 44 patients with recurrent ovarian or triple negative breast cancer were enrolled. Median age 56 years; 23 patients BRCA mutation carriers; median prior regimens four. Patients received a median of four cycles of veliparib/PLD. Grade 3/4 toxicities were observed in 10% of patients. Antitumor activity was observed in both sporadic and BRCA-deficient cancers. Two BRCA mutation carriers had complete responses. Two BRCA patients developed oral squamous cell cancers after completing this regimen. PLD exposure was observed to be higher when veliparib doses were > 200 mg BID. The RP2D is 200 mg veliparib BID on days 1–14 with 40 mg/m2 PLD on day 1 of a 28-day cycle. Anti-tumor activity was seen in both strata. However, given development of long-term squamous cell cancers and the PK interaction observed, efforts should focus on other targeted combinations to improve efficacy.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号